Overview
The Opportunity
The global antiviral landscape is broken. ViroCarb is building the platform to fix it.
UNMET NEED • MARKET OPPORTUNITY
Of ~270 human viruses, only 10–12 are treatable.
Virus-related disease is rising, and most emerging threats have no countermeasure at all.
THE OPPORTUNITY IN NUMBERS
270
Known human viral infections
~4%
Have any approved treatment
$114B
Antiviral market today
$163B
Projected market (2030)
- 1.Disease-causing human viruses: novelty and legacy. Trends Microbiol. 2022;30(12).
- 2.Infectious disease in an era of global change. Nat Rev Microbiol. 2022;20:193–205.
- 3.Infectious Disease Therapeutics Market Report 2026 — The Business Research Company (July 2026).
THE PROBLEM • OUR SOLUTION
Fighting one virus at a time is a losing race.
Virus-targeted drugs fail as fast as viruses mutate.
TODAY'S MODEL
Always a step behind
- –One drug fights one virus — until it mutates and fails.
- –Every new strain demands a brand-new drug.
- –Vaccines lag behind fast viral evolution.
THE VIROCARB APPROACH
One drug, many viruses
- ✓Selective host-pathway inhibition blocks viral RNA processing, assembly, and release while preserving host cell viability.
- ✓Consistent antiviral activity with a higher barrier to resistance.
Ready to go deeper into the science?
Science